22.418 articles found

USE OF A COMBINATION COMPRISING SAFINAMIDE AND LEVODOPA/PDI IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING PARKINSON'S DISEASE AND COMPOSITIONS AND A KIT COMPRISING SAID COMBINATION FOR SUCH A TREATMENT

Check source for author details

· 2005-10-10

Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment.

Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, Sharabi Y.

Hypertension · 2005-10-10

DOI: 10.1161/01.hyp.0000188052.69549.e4PMID: 16216982

METHODS FOR IDENTIFYING PARKINSON'S DISEASE THERAPEUTICS

ISACSON Ole.

· 2005-10-07

THIENOPYRIDINONE COMPOUNDS AND METHODS OF TREATMENT

DHANOA DALE S, BECKER OREN, NOIMAN SILVIA, WU LAURENCE, LOBERA MERCEDES, MOHANTY PRADYUMNA, MARANTZ YAEL, INBAL BOAZ, SHACHAM SHARON.

· 2005-10-06

THIENOPYRIDINONE COMPOUNDS AND METHODS OF TREATMENT

DHANOA Dale S., BECKER Oren, NOIMAN Silvia, WU Laurence, LOBERA Mercedes, MOHANTY Pradyumna, MARANTZ Yael, INBAL Boaz, SHACHAM Sharon.

· 2005-10-06

Thienopyridinone compounds and methods of treatment

DHANOA DALE S.

· 2005-10-06

Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.

Quik M, McIntosh JM.

J Pharmacol Exp Ther · 2005-10-06

DOI: 10.1124/jpet.105.094375PMID: 16210393

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN.

Exp Neurol · 2005-10-03

DOI: 10.1016/j.expneurol.2005.08.017PMID: 16203001

Modeling the Parkinson's tremor and its treatments.

Haeri M, Sarbaz Y, Gharibzadeh S.

J Theor Biol · 2005-10-01

DOI: 10.1016/j.jtbi.2005.03.014PMID: 15950988

Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.

Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ.

Mov Disord · 2005-10-01

DOI: 10.1002/mds.20511PMID: 15986421

To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?

Marchetti B, Abbracchio MP.

Trends Pharmacol Sci · 2005-10-01

DOI: 10.1016/j.tips.2005.08.007PMID: 16126283

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.

Ritzén A, Mathiesen JM, Thomsen C.

Basic Clin Pharmacol Toxicol · 2005-10-01

DOI: 10.1111/j.1742-7843.2005.pto_156.xPMID: 16176554